 Sierra Oncology Inc NASDAQ: SRRA has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential launch of momelotinib. The Company estimates it held cash cash equivalents of 104.7 million as of December 31, 2021. 